BridgeBio Pharma (BBIO) Operating Leases (2020 - 2026)

BridgeBio Pharma's Operating Leases history runs 7 years deep, the most recent figure standing at $18.7 million for Q1 2026.

• In Q1 2026, Operating Leases rose 279.55% year-over-year to $18.7 million; the TTM figure through Mar 2026 stood at $18.7 million (up 279.55% YoY), while the FY2025 annual figure was $3.8 million, down 18.85% from the prior year.
• Operating Leases came in at $18.7 million for Q1 2026 at BridgeBio Pharma, up from $3.8 million in the prior quarter.
• In the past five years, Operating Leases ranged from a high of $18.7 million in Q1 2026 to a low of $3.4 million in Q3 2025.
• A 5-year average of $9.3 million and a median of $9.0 million in 2023 frame the typical range for Operating Leases.
• Across the five-year window, Operating Leases plunged 47.71% in 2024 and surged 279.55% in 2026, its largest moves.
• BridgeBio Pharma's Operating Leases stood at $12.3 million in 2022, then fell by 26.83% to $9.0 million in 2023, then plunged by 47.71% to $4.7 million in 2024, then fell by 18.85% to $3.8 million in 2025, then surged by 389.5% to $18.7 million in 2026.
• According to Business Quant data, Operating Leases over the past three periods registered $18.7 million, $3.8 million, and $3.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison